# Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular Goiter

> **NCT00454220** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 96 (actual)

## Conditions studied

- Multinodular Goiter

## Interventions

- **OTHER:** Placebo
- **DRUG:** MRrhTSH
- **DRUG:** MRrhTSH

## Key facts

- **NCT ID:** NCT00454220
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2022-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454220, "Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular Goiter". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00454220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*